A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Abroad (travel likely)RecruitingPHASE2
Conditions
Myelodysplastic Syndromes · Chronic Myelomonocytic Leukemia · Clonal Cytopenia of Undetermined Significance
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Miami, Miami, Florida, United States
Contact: Principal Investigator (Sangeetha Venugopal, MD)MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Kelly Chien, MD)
Study leads
Kelly Chien, MD
Principal Investigator
M.D. Anderson Cancer Center